IsoRay, Inc. (ISR)

NYSEAMERICAN: ISR · IEX Real-Time Price · USD
0.386
+0.004 (1.00%)
Dec 2, 2022 4:00 PM EST - Market closed
1%
Market Cap 54.26M
Revenue (ttm) 9.95M
Net Income (ttm) -9.10M
Shares Out 142.07M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 318,172
Open 0.385
Previous Close 0.382
Day's Range 0.37 - 0.406
52-Week Range 0.19 - 0.51
Beta 1.19
Analysts Buy
Price Target 1.02 (+164.5%)
Earnings Date Nov 10, 2022

About ISR

Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based i... [Read more]

Industry Biotechnology
Founded 1983
CEO Lori Woods
Employees 66
Stock Exchange NYSEAMERICAN
Ticker Symbol ISR
Full Company Profile

Financial Performance

In 2022, IsoRay's revenue was $10.80 million, an increase of 7.38% compared to the previous year's $10.05 million. Losses were -$7.27 million, 114.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ISR stock is "Buy." The 12-month stock price forecast is 1.02, which is an increase of 164.52% from the latest price.

Price Target
$1.02
(164.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isor...

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“...

3 weeks ago - Business Wire

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...

3 weeks ago - GlobeNewsWire

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Isoray, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - October 3, 2022) - Rigrodsky Law, P.A. is investigating Isoray, Inc. ("Isoray") (NYSE: ISR) regarding possible breaches of fiduciary duties and other violations o...

2 months ago - Newsfile Corp

ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Isoray, Inc. (NYSE: ISR) and Viewpoint Molecular Targeting, Inc. is fair to Isoray shareh...

2 months ago - Business Wire

Viewpoint Molecular Targeting Announces Transformational Merger

CORALVILLE, IA / ACCESSWIRE / September 29, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncolo...

2 months ago - Accesswire

IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a defini...

2 months ago - GlobeNewsWire

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT

2 months ago - GlobeNewsWire

Isoray's Cesium-131 Featured in Presentations at American Brachytherapy Society's Annual Conference

RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Iso r ay , Inc.'s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presenta...

5 months ago - GlobeNewsWire

Isoray To Host Lunch Symposium At American Brachytherapy Society's Annual Conference

RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposiu...

5 months ago - GlobeNewsWire

IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year

6 months ago - GlobeNewsWire

Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT

7 months ago - GlobeNewsWire

Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference

RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori...

8 months ago - GlobeNewsWire

IsoRay's Cesium-131 Radiation Therapy Shows Favorable Outcomes In Prostate Cancer

Investigators from the University of Pittsburgh School of Medicine have published a clinical study demonstrating favorable outcomes for localized intermediate-risk prostate cancer patients treated with ...

9 months ago - Benzinga

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray's Cesium-131

RICHLAND, Wash., March 02, 2022 (GLOBE NEWSWIRE) -- Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized ...

9 months ago - GlobeNewsWire

IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Isoray Announces Second Quarter Fiscal 2022 Financial Results

Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year

9 months ago - GlobeNewsWire

IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022

Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT

10 months ago - GlobeNewsWire

Isoray Announces First Quarter Fiscal 2022 Financial Results

Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year

1 year ago - GlobeNewsWire

Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021

Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT

1 year ago - GlobeNewsWire